Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?

References

• Bishop JA. Lentigos, Melanocytic Naevi and Melanoma. In: Burns T, Breathnach S, Cox N, Griffiths N, eds. Rook's textbook of Dermatology. Wiley-Blackwell, 2010:1-5
   Google Scholar
• Bauer AJ, Stratakis CA. The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet 2005; 42:801-10; PMID:15958502; http://dx.doi.org/10.1136/jmg.2003.017806
   PubMedGoogle Scholar
• Santoro C, Pacileo G, Limongelli G, Scianguetta S, Giugliano T, Piluso G, Ragione FD, Cirillo M, Mirone G, Perrotta S. LEOPARD syndrome: clinical dilemmas in differential diagnosis of RASopathies. BMC Med Genet 2014; 15:44; PMID:24767283; http://dx.doi.org/10.1186/1471-2350-15-44
   PubMedGoogle Scholar
• Kim MS, Youn SH, Na CH, Kim JK, Shin BS. Generalized eruptive lentiginosis in a healthy elderly man. Ann Dermatol 2014; 26:649-50; PMID:25324666; http://dx.doi.org/10.5021/ad.2014.26.5.649
   PubMedGoogle Scholar
• Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011; 10:481-90; PMID:21538076; http://dx.doi.org/10.1007/s10689-011-9446-x
   PubMedGoogle Scholar
• Bezniakow N, Gos M, Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes. Dev Period Med 2014; 18:285-96; PMID:25182392
   PubMedGoogle Scholar
• Uhlenhake EE, Watson AC, Aronson P. Sorafenib induced eruptive melanocytic lesions. Dermatol Online J 2013; 19:18184; PMID:24011281
   PubMedGoogle Scholar
• Costa LA, Belinchon I, Betlloch I, Perez-Crespo M, Mataix J. Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept. Dermatol Online J 2008; 14:11; PMID:18319028
   PubMedGoogle Scholar
• Guttierez-Gonzalez E, Batalla A, de la Mano D. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy. Dermatol Online J 2014; 20:22338; PMID:24746301
   PubMedGoogle Scholar
• Gonzalez-Sixto B, Florez A, Conde Taboada A, De la Torre C, Cruces M. Bilateral segmental lentiginosis associated with malignant melanomas. J Eur Acad Dermatol Venereol 2008; 22:1262-3; PMID:18393964; http://dx.doi.org/10.1111/j.1468-3083.2008.02620.x
   PubMedGoogle Scholar
• Wang YT, Taylor E, Binder S, Mandel H. Bilateral segmental eruptive lentiginosis in a patient with a history of hepatocellular carcinoma. Skinmed 2014; 12:64-5; PMID:24720090
   PubMedGoogle Scholar
• Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013; 19:1933-40; PMID:23406773; http://dx.doi.org/10.1158/1078-0432.CCR-12-0284
   PubMed Web of Science ®Google Scholar
• Pretel M, Irarrazaval I, Aguado L, Lera JM, Navedo M, Gimenez de Azcarate A. Partial unilateral lentiginosis treated with alexandrite Q-switched laser: case report and review of the literature. J Cosmet Laser Ther 2013; 15:207-9; PMID:23384078; http://dx.doi.org/10.3109/14764172.2012.758384
   PubMed Web of Science ®Google Scholar
• Akalin I, Armangil D, Durmus A. Neonatal Polycythemia May be Free of JAK2V617F Mutation. Turkiye Klinikleri J Med Sci 2013; 33:132-7; http://dx.doi.org/10.5336/medsci.2012-29432
   Google Scholar
• Posfai E, Marton I, Kiss-Laszlo Z, Kotosz B, Szell M, Borbenyi Z. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia. Eur Rev Med Pharmacol Sci 2014; 18:3810-8; PMID:25555871
   PubMed Web of Science ®Google Scholar
• Durmus A, Mentese A, Yilmaz M, Sumer A, Akalin I, Topal C, Alver A. The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. Med Princ Pract 2014; 23:253-8; PMID:24642873; http://dx.doi.org/10.1159/000360102
   PubMedGoogle Scholar
• Akada H, Akada S, Hutchison RE, Sakamoto K, Wagner KU, Mohi G. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells 2014; 32:1878-89; PMID:24677703; http://dx.doi.org/10.1002/stem.1711
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24:1128-38; PMID:20428194; http://dx.doi.org/10.1038/leu.2010.69
   PubMed Web of Science ®Google Scholar
• Durmus A, Mentese A, Yilmaz M, Sumer A, Akalin I, Topal C, Alver A. Increased oxidative stress in patients with essential thrombocythemia. Eur Rev Med Pharmacol Sci 2013; 17:2860-6; PMID:24254553
   PubMed Web of Science ®Google Scholar
• Finbloom DS, Larner AC. Regulation of the Jak/STAT signalling pathway. Cell Signal 1995; 7:739-45; PMID:8593242; http://dx.doi.org/10.1016/0898-6568(95)02004-7
   PubMedGoogle Scholar
• Li MY, Tian Y, Shen L, Buettner R, Li HZ, Liu L, Yuan YC, Xiao Q, Wu J, Jove R. Three-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells. Biochem Pharmacol 2013; 86:1411-8; PMID:24021352; http://dx.doi.org/10.1016/j.bcp.2013.08.065
   PubMedGoogle Scholar
• Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu J, Wang Y, Xu RZ, Huang W, Horne DA, et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol 2012; 6:484-93; PMID:22717603; http://dx.doi.org/10.1016/j.molonc.2012.05.002
   PubMed Web of Science ®Google Scholar
• Aftimos PG, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. Int J Oncol 2013; 43:919-26; PMID:23835698
   PubMed Web of Science ®Google Scholar
• Liu-Smith F, Poe C, Farmer PJ, Meyskens FL, Jr. Amyloids, melanins and oxidative stress in melanomagenesis. Exp Dermatol 2014; 24(3):171-4; PMID:25271672
   PubMed Web of Science ®Google Scholar
• Koopmans SM, Schouten HC, van Marion AM. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. Histol Histopathol 2015; 30:151-61; PMID:25196073
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Haslam K, Linders J, Percy MJ, Conneally E, Hayat A, Hennessy B, Leahy M, Murphy K, Murray M, et al. Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Fam Cancer 2014; 13:659-63; PMID:25103330; http://dx.doi.org/10.1007/s10689-014-9743-2
   PubMedGoogle Scholar
• Koh SP, Yip SP, Lee KK, Chan CC, Lau SM, Kho CS, Lau CK, Lin SY, Lau YM, Wong LG, et al. Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study. BMC Genet 2014; 15:147; PMID:25526816; http://dx.doi.org/10.1186/s12863-014-0147-y
   PubMedGoogle Scholar
• Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol 2010; 3:323-37; PMID:21082983; http://dx.doi.org/10.1586/ehm.10.28
   PubMed Web of Science ®Google Scholar
• Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal 2014; 7:ra122; PMID:25538080
   PubMed Web of Science ®Google Scholar